Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 217087-09-7
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram
Supply Ability: G,KG,TON
Appearance:: |
Off-white Powder |
CAS NO:: |
217087-09-7 |
Molecular Formula:: |
C34H42MgN6O9S2 |
Molecular Weight:: |
767.16700 |
EINECS NO:: |
669-839-3 |
MDL NO:: |
MFCD07698573 |
Appearance:: |
Off-white Powder |
CAS NO:: |
217087-09-7 |
Molecular Formula:: |
C34H42MgN6O9S2 |
Molecular Weight:: |
767.16700 |
EINECS NO:: |
669-839-3 |
MDL NO:: |
MFCD07698573 |
Product Description:
Product Name: Esomeprazole magnesium trihydrate CAS NO: 217087-09-7
Synonyms:
Esomeprazole magnesium;
(S)-Omeprazole magnesium trihydrate;
5-m-ethoxy-2-[(4-m-ethoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]benzimidazol-1-ide;
Chemical & Physical Properties:
Appearance: Off-white powder
Assay :≥99.0%
Boiling Point: 600℃ at 760 mmHg
Melting Point: 184-189℃ (dec.)
Flash Point: 316.7℃
Vapor Pressure: 2.35E-14mmHg at 25℃
StorageTemp: -20℃ Freezer
Solubility: Slightly soluble in water, soluble in methanol, practically insoluble in heptane.
Safety Information:
Hazard Code: Xn
Risk Statements: R22
WGK Germany: 3
HS Code: 2933399090
S-Form of Omeprazole. Gastric proton-pump inhibitor.
esomeprazole magnesium trihydrate for the healing of peptic ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.
Zollinger-Ellison syndrome
Peptic ulcer, site unspecified
Duodenal ulcer
Gastric ulcer
Gastro-oesophageal reflux disease
Esomeprazole belongs to the family of medications known as proton pump inhibitors (PPIs). Esomeprazole is registered by the Therapeutic Goods Administration (TGA) for the following indications:
Gastro-Oesophageal Reflux Disease (GORD):
treatment of erosive reflux oesophagitis;
long-term management of patients with healed oesophagitis to prevent relapse;
symptomatic treatment of gastro-oesophageal reflux disease (GORD).
In combination with appropriate antibiotics for:
healing of duodenal ulcer associated with Helicobacter pylori;
eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
Short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) (non-selective and COX-2 selective) therapy.
Healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.
Prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.